Cargando…

Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8

BACKGROUND: Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threatening neurodegenerative diseases, neuronal ceroid lipofuscinosis (NCL). Effective therapy is limited to a single drug for treatment of ceroid lipofuscinosis type 2, necessitating animal disease models t...

Descripción completa

Detalles Bibliográficos
Autores principales: Salpeter, Elyse M., Leonard, Brian C., Lopez, Antonio J., Murphy, Christopher J., Thomasy, Sara, Imai, Denise M., Grimsrud, Kristin, Lloyd, K. C. Kent, Yan, Jiong, Sanchez Russo, Rossana, Shankar, Suma P., Moshiri, Ala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421982/
https://www.ncbi.nlm.nih.gov/pubmed/34532411
http://dx.doi.org/10.21037/atm-20-4739
_version_ 1783749191809368064
author Salpeter, Elyse M.
Leonard, Brian C.
Lopez, Antonio J.
Murphy, Christopher J.
Thomasy, Sara
Imai, Denise M.
Grimsrud, Kristin
Lloyd, K. C. Kent
Yan, Jiong
Sanchez Russo, Rossana
Shankar, Suma P.
Moshiri, Ala
author_facet Salpeter, Elyse M.
Leonard, Brian C.
Lopez, Antonio J.
Murphy, Christopher J.
Thomasy, Sara
Imai, Denise M.
Grimsrud, Kristin
Lloyd, K. C. Kent
Yan, Jiong
Sanchez Russo, Rossana
Shankar, Suma P.
Moshiri, Ala
author_sort Salpeter, Elyse M.
collection PubMed
description BACKGROUND: Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threatening neurodegenerative diseases, neuronal ceroid lipofuscinosis (NCL). Effective therapy is limited to a single drug for treatment of ceroid lipofuscinosis type 2, necessitating animal disease models to facilitate further therapeutic development. Murine models are advantageous for therapeutic development due to easy genetic manipulation and rapid breeding, however appropriate genetic models need to be identified and characterized before being used for therapy testing. To date, murine models of ocular disease associated with ceroid lipofuscinosis type 8 have only been characterized in motor neuron degeneration mice. METHODS: Cln8(−/−) mice were produced by CRISPR/Cas9 genome editing through the International Mouse Phenotyping Consortium. Ophthalmic examination, optical coherence tomography, electroretinography, and ocular histology was performed on Cln8(−/−) mice and controls at 16 weeks of age. Quantification of all retinal layers, retinal pigmented epithelium, and the choriocapillaris was performed using images acquired with ocular coherence tomography and planimetry of histologic sections. Necropsy was performed to investigate concurrent systemic abnormalities. Clinical correlation with human patients with CLN8-associated retinopathy is provided. RESULTS: Retinal degeneration characterized by retinal pigment epithelium mottling, scattered drusen, and retinal vascular attenuation was noted in all Cln8(−/−) mice. Loss of inner and outer photoreceptor segment demarcation was noted on optical coherence tomography, with significant thinning of the whole retina (P=1e-9), outer nuclear layer (P=1e-9), and combined photoreceptor segments (P=1e-9). A global reduction in scotopic and photopic electroretinographic waveforms was noted in all Cln8(−/−) mice. Slight thickening of the inner plexiform layer (P=0.02) and inner nuclear layer (P=0.004), with significant thinning of the whole retina (P=0.03), outer nuclear layer (P=0.01), and outer photoreceptor segments (P=0.001) was appreciated on histologic sections. Scattered lipid vacuoles were noted in splenic red pulp of all Cln8(−/−) mice, though no gross systemic abnormalities were detected on necropsy. Retinal findings are consistent with those seen in patients with ceroid lipofuscinosis type 8. CONCLUSIONS: This study provides detailed clinical characterization of retinopathy in adult Cln8(−/−) mice. Findings suggest that Cln8(−/−) mice may provide a useful murine model for development of novel therapeutics needed for treating ocular disease in patients with ceroid lipofuscinosis type 8.
format Online
Article
Text
id pubmed-8421982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-84219822021-09-15 Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8 Salpeter, Elyse M. Leonard, Brian C. Lopez, Antonio J. Murphy, Christopher J. Thomasy, Sara Imai, Denise M. Grimsrud, Kristin Lloyd, K. C. Kent Yan, Jiong Sanchez Russo, Rossana Shankar, Suma P. Moshiri, Ala Ann Transl Med Original Article on Novel Tools and Therapies for Ocular Regeneration BACKGROUND: Ceroid lipofuscinosis type 8 belongs to a heterogenous group of vision and life-threatening neurodegenerative diseases, neuronal ceroid lipofuscinosis (NCL). Effective therapy is limited to a single drug for treatment of ceroid lipofuscinosis type 2, necessitating animal disease models to facilitate further therapeutic development. Murine models are advantageous for therapeutic development due to easy genetic manipulation and rapid breeding, however appropriate genetic models need to be identified and characterized before being used for therapy testing. To date, murine models of ocular disease associated with ceroid lipofuscinosis type 8 have only been characterized in motor neuron degeneration mice. METHODS: Cln8(−/−) mice were produced by CRISPR/Cas9 genome editing through the International Mouse Phenotyping Consortium. Ophthalmic examination, optical coherence tomography, electroretinography, and ocular histology was performed on Cln8(−/−) mice and controls at 16 weeks of age. Quantification of all retinal layers, retinal pigmented epithelium, and the choriocapillaris was performed using images acquired with ocular coherence tomography and planimetry of histologic sections. Necropsy was performed to investigate concurrent systemic abnormalities. Clinical correlation with human patients with CLN8-associated retinopathy is provided. RESULTS: Retinal degeneration characterized by retinal pigment epithelium mottling, scattered drusen, and retinal vascular attenuation was noted in all Cln8(−/−) mice. Loss of inner and outer photoreceptor segment demarcation was noted on optical coherence tomography, with significant thinning of the whole retina (P=1e-9), outer nuclear layer (P=1e-9), and combined photoreceptor segments (P=1e-9). A global reduction in scotopic and photopic electroretinographic waveforms was noted in all Cln8(−/−) mice. Slight thickening of the inner plexiform layer (P=0.02) and inner nuclear layer (P=0.004), with significant thinning of the whole retina (P=0.03), outer nuclear layer (P=0.01), and outer photoreceptor segments (P=0.001) was appreciated on histologic sections. Scattered lipid vacuoles were noted in splenic red pulp of all Cln8(−/−) mice, though no gross systemic abnormalities were detected on necropsy. Retinal findings are consistent with those seen in patients with ceroid lipofuscinosis type 8. CONCLUSIONS: This study provides detailed clinical characterization of retinopathy in adult Cln8(−/−) mice. Findings suggest that Cln8(−/−) mice may provide a useful murine model for development of novel therapeutics needed for treating ocular disease in patients with ceroid lipofuscinosis type 8. AME Publishing Company 2021-08 /pmc/articles/PMC8421982/ /pubmed/34532411 http://dx.doi.org/10.21037/atm-20-4739 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article on Novel Tools and Therapies for Ocular Regeneration
Salpeter, Elyse M.
Leonard, Brian C.
Lopez, Antonio J.
Murphy, Christopher J.
Thomasy, Sara
Imai, Denise M.
Grimsrud, Kristin
Lloyd, K. C. Kent
Yan, Jiong
Sanchez Russo, Rossana
Shankar, Suma P.
Moshiri, Ala
Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
title Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
title_full Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
title_fullStr Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
title_full_unstemmed Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
title_short Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
title_sort retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8
topic Original Article on Novel Tools and Therapies for Ocular Regeneration
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421982/
https://www.ncbi.nlm.nih.gov/pubmed/34532411
http://dx.doi.org/10.21037/atm-20-4739
work_keys_str_mv AT salpeterelysem retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT leonardbrianc retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT lopezantonioj retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT murphychristopherj retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT thomasysara retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT imaidenisem retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT grimsrudkristin retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT lloydkckent retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT yanjiong retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT sanchezrussorossana retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT shankarsumap retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8
AT moshiriala retinaldegenerationinmiceandhumanswithneuronalceroidlipofuscinosistype8